MedTrace Logo

Systemic Propranolol for the Treatment of Paediatric Patients With Infantile Hemangiomas

NCT04651049 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 128

Last updated 2020-12-03

No results posted yet for this study

Summary

This is retrospective study. The patients treated with oral propranolol at a dose of 2.0 mg/kg per day. Growth parameters (height and weight) were measured at the beginning, the end of treatment and 2 years after treatment. The weight-for-age Z-score (WAZ), height-for-age Z-score (HAZ) and weight-for-height Z-score (WHZ) calculated by the WHO Anthro software were used to assess physical development, and the WHO Child Growth Standards were used as the standards.

Conditions

  • Infantile Haemangiomas

Interventions

DRUG

propranolol

This retrospective study included 128 patients treated with oral propranolol at a dose of 2.0 mg/kg per day.

DEVICE

Sponsors & Collaborators

  • Qilu Hospital of Shandong University

    lead OTHER

Principal Investigators

  • Shaohua Liu, Dr. · Qilu Hospital of Shandong University

Eligibility

Min Age
2 Weeks
Max Age
54 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-15
Primary Completion
2017-12-15
Completion
2020-02-10
FDA Drug
Yes
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04651049 on ClinicalTrials.gov